



Preliminary Phase II Data Show AHCC® Supplementation May Support the Host Immune System to Eradicate the Human Papilloma Virus (HPV) in Women

Scottsdale, AZ (Nov 5, 2018)—Preliminary results from one of the presentations made at the recent [Society for Integrative Oncology 15th international conference](#) in Scottsdale, Arizona, showed that that daily supplementation with AHCC® could support the host immune system to eradicate Human Papilloma Virus (HPV) infection in women with HPV-positive PAP smears.

Early results of the ongoing clinical trial evaluating AHCC® for treatment of HPV were presented by principle investigator Dr. Judith A. Smith of McGovern Medical at The University of Texas Health Science Center at Houston (UTHealth). The randomized, double-blind, placebo-controlled study is following 50 women for up to 12 months, with one group taking six capsules, each containing 500 milligrams of AHCC® (n=25), and a second cohort receiving placebo (n=25).

At the time of the preliminary analysis, 46 patients had completed the study. The results showed that at six months, 58.8 percent of the patients taking AHCC® showed no signs of the infection. In the placebo group, one patient showed no signs of the infection at three, six, 9 and 12 months of study. AHCC® was well-tolerated in patients who received it.

“There currently is no standard of care for persistent, high-risk HPV infections so we have been taking a systematic approach over the past 10 years with our research. We have studied AHCC® from bench studies and two pilot studies that supported rationale for our current ongoing phase II clinical trial to evaluate AHCC® supplementation to support the host immune system to clear persistent HPV infections” Smith said about her research. “The goal of our research is to offer women a safe, clinically evaluated approach to clear persistent HPV infections.”

[What is AHCC®?](#)

AHCC® is a natural immune-modulating compound derived from a unique fraction of specially-cultured medicinal mushroom mycelia (roots) which has been clinically proven to modulate the immune system. AHCC® is supported by more than 30 human clinical studies and more than 50 papers in PubMed-indexed journals (ahccresearch.com/pages/cs).

Studies indicate that AHCC® works as an immunotherapy by using the body’s own immune system to help fight disease. Human and pre-clinical studies have shown that AHCC® increases the number and/or activity of natural killer (NK) cells, killer T-cells, dendritic cells, and cytokines, which enable the body to effectively respond to infections.

Previous clinical research on AHCC® has focused on oncology and hepatology. One 10-year prospective cohort study published in the Journal of Hepatology followed 269 patients with advanced hypercellular carcinoma showed that those taking AHCC® had statistically significant lower tumor recurrence rates (34.5% vs 66.1%) and longer 5-year survival rates



(79.6% vs 53.2%). Multiple other studies have demonstrated that AHCC® improves immune parameters and quality of life of cancer patients. In the field of hepatology, AHCC® has been shown to reduce viral loads in patients with hepatitis C and to help subjects with non-viral liver disease.

HPV is the latest indication for which the benefits of AHCC® are being explored.

Mission of the AHCC Research Association

The mission of the AHCC Research Association is to increase public awareness of AHCC® in integrative medicine, educate patients and doctors on the preventative and therapeutic benefits of AHCC®, and to support further clinical research. The association is committed to advancing the clinical validation of the natural compound “AHCC®”, which is commercially available under various nutritional supplement brands throughout the world.

For more information, please visit: <https://ahccresearch.org/> or contact us at info@ahccresearch.org.

###